.Nature Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires addition of patients with MASLD and also size of liver results in cardio-- renal-- metabolic trials, when data recommend mechanistically possible benefits and also professional protection-- as well as describes considerations for trial concept and governing approval.